Cargando…
Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
The current standard of care for hepatitis C virus (HCV) infection – combination therapy with pegylated interferon and ribavirin – elicits sustained responses in only ∼50% of the patients treated. No alternatives exist for patients who do not respond to combination therapy. Addition of ribavirin sub...
Autores principales: | Krishnan, Sheeja M., Dixit, Narendra M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033369/ https://www.ncbi.nlm.nih.gov/pubmed/21304937 http://dx.doi.org/10.1371/journal.pcbi.1001072 |
Ejemplares similares
-
Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus
por: Wu, LS, et al.
Publicado: (2016) -
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019) -
Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017) -
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016) -
Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)